Sanità

L’Ema dà l’ok al vaccino Novavax: è il quinto in Ue

Si parla del quinto vaccino approvato dall'inizio dell'epidemia

A vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London Wednesday, Oct. 7, 2020. Novavax Inc. said Thursday Jan. 28, 2021 that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated strains of the virus circulating in that country and South Africa. (AP Photo/Alastair Grant)
A dose of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London Wednesday, Oct. 7, 2020. Novavax Inc. said Thursday Jan. 28, 2021 that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated strains of the virus circulating in that country and South Africa. (AP Photo/Alastair Grant)
A vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London Wednesday, Oct. 7, 2020. Novavax Inc. said Thursday Jan. 28, 2021 that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated strains of the virus circulating in that country and South Africa. (AP Photo/Alastair Grant)
Phase 3 Novavax coronavirus vaccine trial vaccine volunteer Franklyn Howe is given an injection at St George's University hospital at in London, Wednesday, Oct. 7, 2020. Novavax Inc. said Thursday Jan. 28, 2021 that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated strains of the virus circulating in that country and South Africa. (AP Photo/Alastair Grant)

Arriva l’ok anche per Novavax dall’Agenzia europea del farmaco. Il prodotto commercializzato da Nuvaxovid è il quinto che viene autorizzato in Europa da inizio pandemia. Novavax è a base di proteine e i dati esaminati dall’Ema mostrano dati soddisfacenti per efficacia, sicurezza e qualità. Gli studi hanno riscontrato una riduazione di circa il 90% del numero di casi sintomatici di Covid-19 da sette giorni dopo la seconda dose. «La sicurezza e l’efficacia del vaccino – si legge in una nota – cotinueranno a essere monitorate man mano che viene utilizzato in tutta l’Unione europea, attraverso il sistema di farmacovigilanza dell’Ue e ulteriori studi da parte dell’azienda e delle autorità europee».

Guarda anche

Società
Buona giornata della felicità

Buona giornata della felicità

di
Salute
Una giornata per curare il cuore

Una giornata per curare il cuore

di

I più visti della settimana

Società
Buona giornata della felicità

Buona giornata della felicità

di
Edicola Digitale Città Nuova - Reader Scarica l'app
Simple Share Buttons